Cel-Sci Corp., of Vienna, Va., said it received approximately $3 million through the exercise of warrants to purchase its common stock over the past 45 days. Read More
Medimmune, of Gaithersburg, Md., the global biologics research and development arm of Astrazeneca plc, and the University System of Maryland said that the initial research collaboration between MedImmune and the University of Maryland, Baltimore (UMB) has been expanded to include the University of Maryland, College Park and the University of Maryland, Baltimore County. Read More
Biogen Idec Inc., of Cambridge, Mass., announced two-year phase III data from the ADVANCE trial for Plegridy (peginterferon beta-1a) in relapsing multiple sclerosis (MS) patients. The data, which were presented at the 66th American Academy of Neurology annual meeting in Philadelphia, demonstrated favorable results on relapse rates, magnetic resonance imaging findings and disease progression when dosed every two weeks. Read More
Actavis plc, of Dublin, said its subsidiary, Watson Laboratories Inc., filed suit against the FDA regarding its entitlement to shared 180-day marketing exclusivity for its generic version of Celebrex (celecoxib) 50 mg, 100 mg, 200 mg and 400 mg capsules. Read More
Upsher-Smith Laboratories Inc., of Maple Grove, Minn., reported phase I data for USL261 (investigational intranasal midazolam) in patients with epilepsy were presented at the 66th Annual American Academy of Neurology (AAN) meeting in Philadelphia. Read More
United Therapeutics Corp., of Silver Spring, Md., reported revenues of $289.4 million for its first quarter ending March 31, up from $25.1 million in the same period last year, and net income of $137.5 million for the quarter, compared to $62.3 million for the same period in 2013. Read More
A rejiggered phase III Fabry disease trial with migalastat, the oral small-molecule chaperone for alpha-galactosidase A, did the trick for Amicus Therapeutics Inc., which reported favorable data in patients with the amenable mutations using the drug as a monotherapy. Read More
The potential $725 million acquisition of Ipierian Inc. by Bristol-Myers Squibb Co. (BMS) merited less than two minutes in the big pharma's first quarter earnings call Tuesday morning and garnered only a single question from analysts. Still, the deal for the San Francisco-based biotech raised tantalizing questions about the direction of its tau program in the hands of a pharma better known for cardiovascular and oncology drug development. Read More
Shares in Transgene SA dropped 15 percent Tuesday as Novartis AG decided not to trigger an option on its therapeutic vaccine TG4010, which is currently undergoing a phase IIb/III trial in non-small-cell lung cancer (NSCLC). Read More
SHANGHAI – Authorities in Beijing are loosening price controls for a select number of commonly used, low-cost medicines. While few innovative drugs are expected to be affected, the move signals the government is willing to take a step back when necessary in its ongoing efforts to rein in drug costs. Read More
The Supreme Court opened the door Tuesday to more awards of attorney fees in patent infringement suits when it unanimously reversed the Federal Circuit in Octane Fitness LLC v. Icon Health & Fitness Inc. Read More
SAN FRANCISCO – Following 2013's strong dealmaking streak, the first quarter of 2014 is carrying its momentum, evidenced by 587 announced deals and $49.7 billion in total disclosed deal value, according to data released at Allicense 2014, in San Francisco. Read More
LONDON – Older men who have lost the Y chromosome from their peripheral blood cells are significantly more likely to develop cancer and to die than those who retain the Y chromosome in their blood cells, a study in Sweden has found. Read More
